SNAP-8
Skin Health & Anti-AgingResearch Use OnlyLast reviewed: September 28, 2026
Quick Facts
- What it is
- A synthetic eight-amino-acid cosmetic peptide — INCI name acetyl octapeptide-3, sold to formulators and to research buyers under the trade name SNAP-8.
- How it's taken
- Topical in every published study — a formulation ingredient in creams, serums and dissolving microneedle patches. No study of an injected form was located.
- Half-life
- Not characterized — no pharmacokinetic data published for this ingredient
- Typical research dose
- No dose exists — it is a formulation ingredient at a manufacturer-set concentration, and neither cited study reports that concentration
- Research status
- A cosmetic ingredient, not an approved drug. Two clinical studies name it; neither tests it in isolation.
On this page
Where to source SNAP-8
SNAP-8 reaches consumers two ways that should not be confused. As acetyl octapeptide-3 it is a cosmetic ingredient inside finished skincare products. As “SNAP-8” it is also sold as raw lyophilised material by research peptide vendors, labelled for laboratory use only. The vendors below are the ones whose price data Prof. Peptide tracks for the raw material.
Two independent labs · per-product COAs
Vanguard Labs · ISO 17025 accredited
Also stocking SNAP-8
Peptides.gg, Ameano Peptides, EZ Peptides, Fusion Peptide — each carries a current price row for this compound.
What is SNAP-8?
SNAP-8 is the trade name for acetyl octapeptide-3, a synthetic eight-amino-acid peptide used as an ingredient in topical cosmetic products. On a product label it appears under its INCI name rather than its trade name. It belongs to the family of acetylated short peptides marketed for the appearance of expression lines, alongside acetyl hexapeptide-8 (Argireline) — a different, shorter molecule with a separate evidence base.
What makes this profile short is the state of the literature, not a shortage of interest in the ingredient. Two clinical studies name acetyl octapeptide-3, and both tested it as one active among several inside a finished patch. No published study located here tests the peptide on its own, in humans or in cell culture. Everything below is reported with that constraint attached, because it is the single most important thing to know about this compound. New to peptide research? Start with the basics
Reported in the cited studies: improvement in eye wrinkles, trans-epidermal water loss and skin elasticity against a placebo patch over 28 days [1]; and reductions in fine lines and wrinkles with increases in hydration, density and thickness over 12 weeks without a control arm [2]. Both results belong to multi-ingredient products.
The library's other Skin Health & Anti-Aging entries include GLOW and GHK-Cu.
What is SNAP-8 proposed to do?
The mechanism attributed to SNAP-8 is not one this profile can support from a study of SNAP-8. It is reported below as a proposed mechanism, with its actual provenance named.
- The proposed mechanism. Acetyl octapeptide-3 is marketed on the rationale that it interferes with assembly of the SNARE complex, the protein machinery that lets a nerve terminal release its neurotransmitter — reducing the muscle contraction that creates expression lines. Prof. Peptide located no published study testing this for acetyl octapeptide-3.
- Where that rationale comes from [3]. The SNARE account belongs to acetyl hexapeptide-8 (Argireline), a six-amino-acid peptide and a different molecule, which does have a randomized placebo-controlled anti-wrinkle trial (Wang et al. 2013). Structural similarity is not shared evidence, and this profile does not treat Argireline's trial record as SNAP-8's.
- What the clinical studies measured [1][2]. Both studies that name acetyl octapeptide-3 measured skin outcomes — wrinkle depth, hydration, elasticity, trans-epidermal water loss — not neurotransmitter release. No mechanistic endpoint was reported in either.
What does the research on SNAP-8 show?
A PubMed search for acetyl octapeptide-3 and SNAP-8 returned two clinical studies that genuinely name the ingredient. Both tested it inside a multi-ingredient product. The central limitation of this compound's evidence base is therefore not sample size or study quality — it is attribution.
- Split-eye placebo-controlled microneedle patch, n=24 [1]. A dissolving microneedle patch containing acetyl octapeptide-3, L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid was compared against a hyaluronic-acid-only placebo patch on the opposite eye, over 28 days. The active patch showed better eye-wrinkle improvement, lower trans-epidermal water loss and greater elasticity, with no adverse effects reported (Shin et al. 2024). The study was run by the patch manufacturer, and the active arm carries three actives.
- Uncontrolled 12-week formulation study [2]. A monocentric study of a hyaluronic-acid patch loaded with five actives including acetyl octapeptide-3 reported a 25.8% reduction in fine lines and wrinkles, 15.4% higher hydration, 14.2% higher density and 12.9% greater thickness (Avcil et al. 2020). There is no control arm, and the authors write that the ingredients "might possibly be acted synergistically".
- No single-ingredient study. Prof. Peptide found no published trial, and no in-vitro report, testing acetyl octapeptide-3 in isolation. Every effect above is an effect of a mixture that contained it.
How is SNAP-8 used, and what is reported about tolerability?
There is no dose for SNAP-8 in the sense that word carries for a drug. In the published studies it is a formulation ingredient at a manufacturer-set concentration, applied to the skin. Tolerability is reported here in the same section, because the two questions are not separable for a compound whose only human data come from those same two products.
In both cited studies acetyl octapeptide-3 was delivered topically: as a component of a dissolving microneedle patch applied overnight [1], and as a component of a hyaluronic-acid microneedle patch used over 12 weeks [2]. Neither paper reports the peptide's concentration in a form that would let a reader reconstruct an exposure, and neither reports pharmacokinetics — no absorption, distribution or half-life figures exist for this ingredient in the literature located here. On tolerability, the 2024 split-eye study reported no adverse effects across 28 days of overnight use [1]; the 2020 study reported the efficacy outcomes above and no safety signal [2]. Both are small, short and run on intact facial skin, so they characterise a cosmetic use pattern and nothing beyond it. Research vendors sell SNAP-8 as a lyophilised vial for laboratory use; Prof. Peptide publishes no reconstitution or injection schedule for it, because no published study has examined a systemic route and there is nothing to report.
What are the limitations of SNAP-8 research?
The binding limitation is attribution. Both clinical studies that name acetyl octapeptide-3 tested it inside a product containing two or four other actives, and one of them says so in its own conclusion. A reader cannot tell from this literature whether the peptide contributed to the reported wrinkle, hydration or elasticity changes, or whether the other ingredients account for all of them.
The mechanism commonly published alongside this ingredient — SNARE-complex interference — has not been demonstrated for acetyl octapeptide-3 in any study located here. It belongs to a different peptide, acetyl hexapeptide-8 (Argireline).
Both studies are small and short: 24 subjects over 28 days, and a single-centre uncontrolled 12-week study. One is manufacturer-run. There is no independent replication, no dose-response work, and no pharmacokinetic characterisation at all.
This profile reports cosmetic and formulation research. It carries no injectable framing, because no source located here supports one.
SNAP-8 FAQ
What is SNAP-8?
SNAP-8 is the trade name for acetyl octapeptide-3, an eight-amino-acid synthetic peptide used as an ingredient in topical cosmetic formulations — creams, serums and dissolving microneedle patches. In cosmetic labelling it appears under its INCI name, acetyl octapeptide-3, not as “SNAP-8”.
Is SNAP-8 FDA-approved?
No. SNAP-8 is not an approved drug. It is used as a cosmetic ingredient, which in the US means it is regulated as a cosmetic rather than reviewed for safety and efficacy as a drug would be. Research-grade material sold by peptide vendors is labelled for laboratory use only.
Is SNAP-8 injected?
Prof. Peptide located no published study of an injected form. Every clinical study identified here applied it to the skin — in one case as a leave-on microneedle patch, in the other as a topical formulation. Research vendors do sell it as a lyophilised vial, which is the same presentation used for injectable research peptides, but that is a packaging fact and not evidence of a studied route.
What does the research on SNAP-8 actually show?
Two clinical studies name acetyl octapeptide-3, and neither tests it on its own. A 2024 split-eye study compared a microneedle patch containing acetyl octapeptide-3, L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid against a placebo patch in 24 subjects, and reported improvement in eye wrinkles. A 2020 uncontrolled 12-week study used a patch carrying acetyl octapeptide-3 alongside four other actives and reported a 25.8% reduction in fine lines and wrinkles. Because both products are mixtures, neither result can be attributed to this peptide.
Is SNAP-8 the same as Argireline?
No. Argireline is acetyl hexapeptide-8, a six-amino-acid peptide. It is a different molecule with its own trial record, including a randomized placebo-controlled anti-wrinkle study. The SNARE-related mechanism often attributed to SNAP-8 in marketing copy comes from work on Argireline, and Prof. Peptide found no published study demonstrating it for acetyl octapeptide-3.
References
- Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical safety and efficacy evaluation of a dissolving microneedle patch having dual anti-wrinkle effects with safe and long-term activities. Ann Dermatol. 2024;36(4):215-224. doi:10.5021/ad.23.136. PMID 39082657. https://pubmed.ncbi.nlm.nih.gov/39082657/
- Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study. J Cosmet Dermatol. 2020;19(2):328-337. doi:10.1111/jocd.13009. PMID 31134751. https://pubmed.ncbi.nlm.nih.gov/31134751/
- Wang Y, Wang M, Xiao S, et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID 23417317. Cited as a contrast — this paper is about acetyl hexapeptide-8, not acetyl octapeptide-3. https://pubmed.ncbi.nlm.nih.gov/23417317/
Published Studies
Plain-English summaries of the peer-reviewed studies behind the statements above. Click any title to read the source paper. Note that neither of the two studies naming acetyl octapeptide-3 tested it on its own.
Shin JY, Han D, Yoon KY, Jeong DH, Park YI.
A split-eye comparative clinical study in 24 healthy subjects. A dissolving microneedle patch containing acetyl octapeptide-3, L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid was applied overnight to one eye and a hyaluronic-acid-only placebo patch to the other, with assessments over 28 days. The active patch outperformed placebo on eye-wrinkle improvement, trans-epidermal water loss and elasticity, with no adverse effects reported. Two caveats belong with the result: the patch is a three-active mixture, so nothing here isolates acetyl octapeptide-3, and the study was conducted by the manufacturer, Raphas Co.
Avcil M, Akman G, Klokkers J, Jeong D, Çelik A.
A single-centre, 12-week, uncontrolled study of a hyaluronic-acid microneedle patch loaded with an arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts. Reported outcomes were a 25.8% reduction in fine lines and wrinkles, 15.4% higher hydration, 14.2% higher density and 12.9% greater thickness. The authors' own conclusion is that the ingredients "might possibly be acted synergistically" — an explicit statement that the design cannot separate them. There is no control arm.
Wang Y, Wang M, Xiao S, et al.
Listed here as a contrast, not as evidence for SNAP-8. This randomized, placebo-controlled trial tested Argireline — acetyl hexapeptide-8, a six-amino-acid peptide — and is the kind of controlled single-ingredient study that acetyl octapeptide-3 does not have. Marketing copy for SNAP-8 routinely borrows Argireline's mechanism; the two are different molecules with different evidence.
Related Peptides
We may earn commissions from peptide vendor affiliate links.
Have a question about SNAP-8? Send us an email